Serum vascular endothelial growth factor and angiopoietin-2 are associated with the severity of systemic inflammation rather than the presence of hemoptysis in patients with inflammatory lung disease

Yonsei Medical Journal

Volumn 53, Issue 2, 2012, Pages 369-376

  Park, Hye Yun ^a   Hahm, Cho Rom ^a   Jeon, Kyeongman ^a   Koh, Won Jung ^a   Suh, Gee Young ^a   Chung, Man Pyo ^a   Kim, Hojoong ^a   Kwon, O Jung ^a   Um, Sang Won ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Angiogenesis; Angiopoietin 2; Hemoptysis; Inflammation; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 2; C REACTIVE PROTEIN; VASCULOTROPIN;

ADULT; AGED; ARTERIAL OXYGEN TENSION; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEMOPTYSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PROSPECTIVE STUDY;

AGED; ANGIOPOIETIN-2; FEMALE; HEMOPTYSIS; HUMANS; INFLAMMATION; LUNG DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863116656     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.2.369     Document Type: Article

References (35)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
2. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11:457-65.
3. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hy-perpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
4. Matsuyama W, Hashiguchi T, Matsumuro K, Iwami F, Hirotsu Y, Kawabata M, et al. Increased serum level of vascular endothelial growth factor in pulmonary tuberculosis. Am J Respir Crit Care Med 2000;162:1120-2.
5. Kanazawa H. Role of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Med Sci Monit 2007;13:RA189-95.
6. Inoue K, Matsuyama W, Hashiguchi T, Wakimoto J, Hirotsu Y, Kawabata M, et al. Expression of vascular endothelial growth factor in pulmonary aspergilloma. Intern Med 2001;40:1195-9.
7. McColley SA, Stellmach V, Boas SR, Jain M, Crawford SE. Serum vascular endothelial growth factor is elevated in cystic fbro-sis and decreases with treatment of acute pulmonary exacerbation. Am J Respir Crit Care Med 2000;161:1877-80.
8. Donovan EA, Kummar S. Targeting VEGF in cancer therapy. Curr Probl Cancer 2006;30:7-32.
9. Mattern J, Koomägi R, Volm M. Association of vascular endothe-lial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-4.
10. Nilsson I, Shibuya M, Wennström S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 2004;299:476-85.
11. Tsigkos S, Koutsilieris M, Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 2003;12: 933-41.
12. Hashizume H, Falcón BL, Kuroda T, Baluk P, Coxon A, Yu D, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70:2213-23.
13. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006;441: 437-43.
14. Boussat S, Eddahibi S, Coste A, Fataccioli V, Gouge M, Housset B, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000;279:L371-8.
15. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007;132:200-6.
16. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
17. Hayes RJ, Bennett S. Simple sample size calculation for cluster-randomized trials. Int J Epidemiol 1999;28:319-26.
18. Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178-87.
19. Alatas F, Alatas O, Metintas M, Ozarslan A, Erginel S, Yildirim H. Vascular endothelial growth factor levels in active pulmonary tuberculosis. Chest 2004;125:2156-9.
20. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, et al. Clinical signifcance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998;34:2041-5.
21. Kikuchi K, Kubo M, Kadono T, Yazawa N, IHN H, Tamaki K. Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 1998;139:1049-51.
22. Futami R, Miyashita M, Nomura T, Makino H, Matsutani T, Sasa-jima K, et al. Increased serum vascular endothelial growth factor following major surgical injury. J Nihon Med Sch 2007;74:223-9.
23. Siner JM, Bhandari V, Engle KM, Elias JA, Siegel MD. Elevated serum angiopoietin 2 levels are associated with increased mortality in sepsis. Shock 2009;31:348-53.
24. van der Heijden M, Pickkers P, van Nieuw Amerongen GP, van Hinsbergh VW, Bouw MP, van der Hoeven JG, et al. Circulating angiopoietin-2 levels in the course of septic shock: relation with fluid balance, pulmonary dysfunction and mortality. Intensive Care Med 2009;35:1567-74.
25. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P, van Hinsbergh VW, Groeneveld AB. Angiopoietin-2, permeability oedema, occurrence and severity of ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008;63:903-9.
26. Ricciuto DR, dos Santos CC, Hawkes M, Toltl LJ, Conroy AL, Rajwans N, et al. Angiopoietin-1 and angiopoietin-2 as clinically informative prognostic biomarkers of morbidity and mortality in severe sepsis. Crit Care Med 2011;39:702-10.
27. Orfanos SE, Kotanidou A, Glynos C, Athanasiou C, Tsigkos S, Dimopoulou I, et al. Angiopoietin-2 is increased in severe sepsis: correlation with infammatory mediators. Crit Care Med 2007;35: 199-206.
28. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY. Plasma an-giopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison with VEGF and Flt-1. Eur J Clin Invest 2003; 33:883-90.
29. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
30. Mandriota SJ, Pyke C, Di Sanza C, Quinodoz P, Pittet B, Pepper MS. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol 2000;156:2077-89.
31. Pichiule P, Chavez JC, LaManna JC. Hypoxic regulation of angio-poietin-2 expression in endothelial cells. J Biol Chem 2004;279: 12171-80.
32. Bruick RK, McKnight SL. Building better vasculature. Genes Dev 2001;15:2497-502.
33. Semenza GL. Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance. J Clin Invest 2001;108:39-40.
34. Lim HS, Lip G Y, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endo-thelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005;180:113-8.
35. Kanazawa H, Nomura S, Asai K. Roles of angiopoietin-1 and an-giopoietin-2 on airway microvascular permeability in asthmatic patients. Chest 2007;131:1035-41.